Background: Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a nuclear-enriched long non-coding RNA, implicated in the tumorigenesis of various cancers, including breast carcinoma (BC). It is associated with cancer proliferation, invasion, migration, and metastasis, and plays a role in immune system modulation.
Aims and Objectives: This in silico study investigates MALAT1's diagnostic, prognostic, and therapeutic potential in BC. It examines MALAT1's differential expression in Breast Cancer (BC) versus normal tissues, its impact on patient survival, and its interaction with miR-561 affecting TOP2A mRNA degradation.
Methodology: Using publicly available datasets from GEO and TCGA, we conducted differential expression, survival, and prognostic analyses, along with network and pathway studies and drug repurposing analyzes and Tools like Graph Pad Prism and GEPIA data set was used for demographics.
Results: Our analyzes indicate overexpression of MALAT1 in BC tissues, its correlation with poorer survival rates, and involvement in key oncogenic pathways. Additionally, drug repurposing analyzes have identified potential MALAT1-targeted therapeutic strategies.
Conclusion: MALAT1 serves as a significant biomarker for BC diagnosis and prognosis and is identified as a potential therapeutic target. This study lays the groundwork for future research into MALAT1-targeted therapies in BC